Author Archives: admin001

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase ...

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+(TM) Development

Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very ...

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS(TM)

(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor ...

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

Over 75 patients enrolled in BriaCell’s pivotal Phase 3 study of Bria-IMT ™ plus immune ...

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) ...